Intestinal FXR agonism synergizes with leptin to improve obesity by reducing appetite via secretin

ABSTRACT: Obesity is a chronic condition and is closely associated with various metabolic diseases. It has become a global health concern, and effective pharmacotherapies are urgently needed. Farnesoid X receptor (FXR) is widely regarded as a pivotal target for the treatment of metabolic diseases because of its many biological functions. To avoid the possible adverse side effects of systemic FXR agonism, intestinal-specific FXR agonists have been developed. They show excellent anti-obesity effects, but the underlying mechanism remains unclear. In this study, we demonstrate that intestinal-restricted FXR agonists exhibit marked anti-obesity effects in diet-induced obesity (DIO) and db/db mice, but not in ob/ob mice. Mechanistically, they suppress appetite to reduce obesity in leptin-dependent and sec

SUBMITTER: Xiaochai Zhu 

PROVIDER: S-SCDT-10_1038-S44319-026-00938-7 | biostudies-other |

REPOSITORIES: biostudies-other